Vir Biotechnology, Inc.: collaboration with Gilead; Gilead buys 1,765,486 shares

What happened

• Vir Biotechnology, Inc. entered into a collaboration and license agreement with Gilead Sciences, Inc. on Oct 9, 2026, to discover and engineer 3 novel PRO-XTEN® dual-masked T-cell engager development candidates targeting selected solid tumor-associated antigens.
• Concurrently, Vir entered into a stock purchase agreement under which Gilead agreed to purchase 1,765,486 shares of Vir common stock at $14.16 per share for an aggregate purchase price of approximately $25,000,000; Vir issued a press release about the agreements on Oct 14, 2026.

Key details

• Collaboration scope: discover and engineer 3 novel PRO-XTEN dual-masked T-cell engager development candidates targeting selected solid tumor-associated antigens.
• Stock purchase terms: 1,765,486 shares at $14.16 per share, aggregate approximately $25,000,000.
• SPA provisions: includes standstill, voting and lockup provisions that expire 1 year after the anticipated closing; 1 year after the anticipated closing Gilead will have, under certain circumstances, a customary right to require Vir to register resale of the shares.
• Securities law reliance: Vir agreed to sell the shares in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, based in part on Gilead’s representation that it is an accredited investor.

Why it may matter

• The filing reports Item 3.02 (unregistered sales of equity securities) for the SPA share sale and Item 8.01 (other events) for the press release announcing the agreements. The filing also contains forward-looking statements describing risks and uncertainties related to the collaboration and development efforts. The filing does not show why the insider traded or why the company acted.